PRISM Cancer Cell Line Drug Sensitivity Study

The contract calls for the execution of a high-throughput PRISM study to assess the drug sensitivity of compound NCGC01219867 across approximately 900 barcoded cancer cell lines using a Luminex-format assay with a 5-day exposure period and an 8-point dose-response dilution series. This effort is designed to generate comprehensive pharmacological profiles for the compound across a broad panel of genetically diverse cancer models, enabling the identification of sensitive and resistant lines, potential biomarkers of response, and differential activity patterns by lineage. The work involves precise handling of cell lines, standardized dosing protocols, and high-precision data collection through the Luminex platform to ensure reproducibility and statistical power across the large-scale screening effort. The initiative is issued as a subcontract under the National Institutes of Health, part of the Department of Health and Human Services, with a NAICS code of 541715 indicating classification under research and development in the physical, engineering, and life sciences. The solicitation was posted on August 7, 2026, with a response deadline of August 24, 2026, and the place of performance is unspecified, suggesting flexibility in location provided the technical requirements are met. There is no set-aside designation or point of contact listed, and the work is focused entirely on experimental execution rather than broader administrative or clinical development tasks.